​​​​​​​Biogen soars as Alzheimer’s approval cheers investors

Could this be the start of a cure for dementia? Biogen shares have rocketed after its Alzheimer’s antibody therapy was approved by U.S. regulators. Here, Robert Langreth explores the uncertainties surrounding the treatment that could dramatically change treatment for the debilitating brain condition.